oNKord is a first-generation off-the-shelf NK cellular immunotherapy product. In the next months, acute myeloid leukemia patients will receive the treatment as a part of a phase I/IIa clinical trial. A phase II trial for multiple myeloma patients is expected to begin in 2021.

Glycostem products are a safe alternative to chimeric antigen receptor (CAR) T-cell therapies that harness the power of stem cell-derived NK cells, according to the firm. oNKord products are manufactured from allogenic raw material, produced in a closed system in the company's facility in the Netherlands. Production includes ex vivo generation of natural killer cells.

oNKord has been successfully evaluated in a phase I clinical trial in acute myeloid leukemia patients, which established safety and clinical activity.

Companies work to develop combo mAb, NK cell COVID-19 therapy
A new research project is bringing together universities and pharmaceutical companies to collaborate on the development of a combination of a monoclonal...

Bristol Myers licenses immunotherapy from Dragonfly
Bristol Myers Squibb has paid $12 million to Dragonfly Therapeutics to license a fourth immunotherapy drug candidate from Dragonfly's TrinKet portfolio.

Avectas, ONK to develop cancer cell therapy
Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy from ONK Therapeutics for the treatment of B-cell malignancies...